J Cancer 2018; 9(5):906-913. doi:10.7150/jca.22014
Alteration of Serum IgG Galactosylation as a Potential Biomarker for Diagnosis of Neuroblastoma
1. Key Laboratory of Glycoconjugate Research Ministry of Public Health, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China
2. Department of Anesthesiology, Children's Hospital, Fudan University, Shanghai 201102, China
3. Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200090, China
4. Department of Oncology, Children's Hospital, Fudan University, Shanghai 201102, China
*These authors contributed equally to this work.
Qin W, Pei H, Qin R, Zhao R, Han J, Zhang Z, Dong K, Ren S, Gu J. Alteration of Serum IgG Galactosylation as a Potential Biomarker for Diagnosis of Neuroblastoma. J Cancer 2018; 9(5):906-913. doi:10.7150/jca.22014. Available from https://www.jcancer.org/v09p0906.htm
Background: Neuroblastoma (NB) is the most frequent pediatric malignant neoplasm that originates from embryonic neural crest cells. Urinary catecholamines in 24-h urine are most commonly analyzed for the diagnosis of neuroblastoma at good sensitivity; however, it is challenging to collect 24-h urine samples in a pediatric population. Therefore, development of more rapid, non-invasive and cost-effective tools for the diagnosis of NB remains needed. Serum immunoglobulin G (IgG) galactosylation have been found highly associated with adult cancers in our previous study.
Methods: To explore the potential use of serum IgG galactosylation in aiding diagnosis of neuroblastoma, serum IgG galactosylation profiles of 26 neuroblastoma cases and 30 age-matched non-malignant controls were analyzed by MALDI MS. The alteration of IgG galactosylation in neuroblastoma patients was measured by a Gal-ratio formula: G0/(G1+G2×2), calculating the relative intensities of agalactosylated N-glycan (G0) vs mono-galactosyl N-glycan (G1) and digalactosyl N-glycan (G2).
Results: The results showed that IgG Gal-ratios were significantly higher in neuroblastoma cases compared with non-malignant controls (p=5.0×10-4). And the Gal-ratio data generated sensitivity and specificity of 84.62% and 60.00%, combined with an AUC (area under the curve) of 0.80.
Conclusions: The analysis of serum IgG galactosylation distribution may play a suggestive role for neuroblastoma diagnosis, or serve as a potential biomarker for NB diagnosis.
Keywords: IgG, Galactosylation, Neuroblastoma, Biomarker, Diagnosis